Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.

Cancer communications (London, England) - 1 Oct 2024

Noeraparast Maxim, Krajina Katarina, Pichler Renate, Niedersüß-Beke Dora, Shariat Shahrokh F, Grünwald Viktor, Ahyai Sascha, Pichler Martin

Abstract excerpt

In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non-muscle-invasive and muscle-invasive forms of the disease. FGFR3 mutations in up to half of BLCAs play a well-established role in tumorigenesis, shaping distinct tumor initiation patterns and impacting the tumor microenvironment (TME). Emphasizing the...

Topics

Join the communities discussing this publication.

Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
Molecular Targeted Therapy
Pyrazoles
Quinoxalines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptor, Fibroblast Growth Factor, Type 3

Tumor Microenvironment

Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39161208
DOI: 10.1002/cac2.12602
PMCID: PMC11483561

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.PMID 39161208Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerSemantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Semantic proximity Read ↗

Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.Semantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.Semantic proximity Read ↗

Fibroblast growth factor receptor-3 in urothelial tumorigenesis.Semantic proximity Read ↗

FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.